Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology
- 26 July 2010
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 107 (32) , 14443-14448
- https://doi.org/10.1073/pnas.0913496107
Abstract
Soluble antigens diffuse out of the brain and can thus stimulate a systemic immune response, whereas particulate antigens (from infectious agents or tumor cells) remain within brain tissue, thus failing to stimulate a systemic immune response. Immune privilege describes how the immune system responds to particulate antigens localized selectively within the brain parenchyma. We believe this immune privilege is caused by the absence of antigen presenting dendritic cells from the brain. We tested the prediction that expression of fms-like tyrosine kinase ligand 3 (Flt3L) in the brain will recruit dendritic cells and induce a systemic immune response against exogenous influenza hemagglutinin in BALB/c mice. Coexpression of Flt3L with HA in the brain parenchyma induced a robust systemic anti-HA immune response, and a small response against myelin basic protein and proteolipid protein epitopes. Depletion of CD4+CD25+ regulatory T cells (Tregs) enhanced both responses. To investigate the autoimmune impact of these immune responses, we characterized the neuropathological and behavioral consequences of intraparenchymal injections of Flt3L and HA in BALB/c and C57BL/6 mice. T cell infiltration in the forebrain was time and strain dependent, and increased in animals treated with Flt3L and depleted of Tregs; however, we failed to detect widespread defects in myelination throughout the forebrain or spinal cord. Results of behavioral tests were all normal. These results demonstrate that Flt3L overcomes the brain9s immune privilege, and supports the clinical development of Flt3L as an adjuvant to stimulate clinically effective immune responses against brain neo-antigens, for example, those associated with brain tumors.Keywords
This publication has 48 references indexed in Scilit:
- Release of HMGB1 in Response to Proapoptotic Glioma Killing Strategies: Efficacy and NeurotoxicityClinical Cancer Research, 2009
- HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor RegressionPLoS Medicine, 2009
- Depletion of CD4+CD25+ T cells exacerbates experimental autoimmune encephalomyelitis induced by mouse, but not rat, antigensJournal of Neuroscience Research, 2009
- Treg Depletion Inhibits Efficacy of Cancer Immunotherapy: Implications for Clinical TrialsPLOS ONE, 2008
- Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma modelNeuro-Oncology, 2008
- One-year Expression From High-capacity Adenoviral Vectors in the Brains of Animals With Pre-existing Anti-adenoviral Immunity: Clinical ImplicationsMolecular Therapy, 2007
- Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammationNature Medicine, 2007
- Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cellsNeuron Glia Biology, 2006
- In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brainThe Journal of Experimental Medicine, 2006
- Rapid Upregulation of Interferon-Regulated and Chemokine mRNAs upon Injection of 108International Units, but Not Lower Doses, of Adenoviral Vectors into the BrainJournal of Virology, 2006